RN7SL646P

Across TCGA pan-cancer cohorts, RN7SL646P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RN7SL646P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RN7SL646P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL646P is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, BRCA, and THCA are the cancer types where RN7SL646P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL646P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.064	.001	4	view →
BRCA	All	All	+0.030	.037	4	view →
THCA	All	All	−0.063	.001	3	view →
ESCA	All	II,III,IV	+0.185	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RN7SL646P–KIRC

Open the KIRC breakdown →